Organon (OGN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $13.76, +0.15% vs the prior close of $13.74.
- Volume 1.98M shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OGN ends flat (+0.1%) to $13.76. Closed at $13.76, +0.15% vs the prior close of $13.74. Day range $13.75–$13.77, opened at $13.75.
OGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — OGN ends flat (+0.1%) to $13.76
- Closed at $13.76, +0.15% vs the prior close of $13.74. Day range $13.75–$13.77, opened at $13.75.
- Volume was 1.98M shares, 0.7x its 50-day average of 2.68M.
- Price is +0.3% vs its 50-day average ($13.72) and +22.9% vs its 200-day average ($11.19).
- 52-week range $5.69–$13.83; today's close sits at 99% of that range, 0.5% below the 52-week high.
Oct 14, 2026 — OGN ends flat (-0.2%) to $13.74, 3 down days in a row
- Closed at $13.74, -0.22% vs the prior close of $13.77. Day range $13.74–$13.77, opened at $13.77.
- Volume was 1.81M shares, 0.7x its 50-day average of 2.68M.
- Price is +0.2% vs its 50-day average ($13.71) and +23.1% vs its 200-day average ($11.16).
- 52-week range $5.69–$13.83; today's close sits at 99% of that range, 0.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — OGN ends flat (+0.0%) to $13.77
- Closed at $13.77, +0.00% vs the prior close of $13.77. Day range $13.76–$13.79, opened at $13.77.
- Volume was 2.89M shares, 1.1x its 50-day average of 2.66M.
- Price is +0.5% vs its 50-day average ($13.71) and +23.8% vs its 200-day average ($11.13).
- 52-week range $5.69–$13.83; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 12, 2026 — OGN ends flat (-0.3%) to $13.77
- Closed at $13.77, -0.29% vs the prior close of $13.81. Day range $13.76–$13.80, opened at $13.80.
- Volume was 932.30K shares, 0.3x its 50-day average of 2.69M — lighter than usual.
- Price is +0.5% vs its 50-day average ($13.70) and +24.1% vs its 200-day average ($11.09).
- 52-week range $5.69–$13.83; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 9, 2026 — OGN rises 0.4% to $13.81, a 52-week high
- Closed at $13.81, +0.44% vs the prior close of $13.75. Day range $13.75–$13.83, opened at $13.76.
- Volume was 3.26M shares, 1.2x its 50-day average of 2.66M.
- Price is +0.8% vs its 50-day average ($13.70) and +24.9% vs its 200-day average ($11.06).
- 52-week range $5.69–$13.83; today's close sits at 100% of that range, 0.1% below the 52-week high.
Oct 8, 2026 — OGN ends flat (-0.3%) to $13.75
- Closed at $13.75, -0.29% vs the prior close of $13.79. Day range $13.75–$13.80, opened at $13.78.
- Volume was 2.09M shares, 0.8x its 50-day average of 2.67M.
- Price is +0.4% vs its 50-day average ($13.69) and +24.7% vs its 200-day average ($11.03).
- 52-week range $5.69–$13.80; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 7, 2026 — OGN rises 0.4% to $13.79, a 52-week high
- Closed at $13.79, +0.36% vs the prior close of $13.74. Day range $13.72–$13.79, opened at $13.72.
- Volume was 2.21M shares, 0.8x its 50-day average of 2.67M.
- Price is +0.7% vs its 50-day average ($13.69) and +25.5% vs its 200-day average ($10.99).
- 52-week range $5.69–$13.79; today's close sits at 100% of that range, at a new 52-week high.
Oct 6, 2026 — OGN ends flat (+0.3%) to $13.74
- Closed at $13.74, +0.29% vs the prior close of $13.70. Day range $13.73–$13.75, opened at $13.74.
- Volume was 1.95M shares, 0.7x its 50-day average of 2.69M.
- Price is +0.4% vs its 50-day average ($13.68) and +25.4% vs its 200-day average ($10.96).
- 52-week range $5.69–$13.78; today's close sits at 99% of that range, 0.3% below the 52-week high.
Oct 5, 2026 — OGN ends flat (-0.1%) to $13.70
- Closed at $13.70, -0.15% vs the prior close of $13.72. Day range $13.70–$13.75, opened at $13.72.
- Volume was 2.88M shares, 1.1x its 50-day average of 2.71M.
- Price is +0.1% vs its 50-day average ($13.68) and +25.4% vs its 200-day average ($10.92).
- 52-week range $5.69–$13.78; today's close sits at 99% of that range, 0.6% below the 52-week high.
Oct 2, 2026 — OGN ends flat (+0.1%) to $13.72
- Closed at $13.72, +0.07% vs the prior close of $13.71. Day range $13.71–$13.75, opened at $13.71.
- Volume was 1.92M shares, 0.7x its 50-day average of 2.80M.
- Price is +0.3% vs its 50-day average ($13.68) and +26.0% vs its 200-day average ($10.89).
- 52-week range $5.69–$13.78; today's close sits at 99% of that range, 0.5% below the 52-week high.
OGN latest news & SEC filings
Every SEC filing by or about OGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 5, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Drinane Juliana Papa sold 14,761 shares at $13.57 (≈$200.31K) on Aug 5, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 31, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 31, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.56B (prior year $1.59B) (-2.3% vs Jun 30, 2025)
- Net income: $108.00M (prior year $145.00M) (-25.5% vs Jun 30, 2025)
- Diluted EPS: $0.40 (prior year $0.56) (-28.6% vs Jun 30, 2025)
Jul 23, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jul 17, 2026 · DEFA14A — Additional proxy materials
Additional proxy materials
Jul 17, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade OGN
- Last results release: Apr 30, 2026 (8-K Item 2.02). Previous ones: Feb 12, 2026, Nov 10, 2025, Aug 5, 2025. Based on that rhythm, the next report is likely around Jul 30, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 0.16% (largest 0.4%). That is a relatively calm stock.
- Liquidity: about 2.19M shares (≈$30.09M) trade per day on average.
- 52-week position: $13.76 vs a range of $5.69–$13.83 (99% of the range).
- Dividends: last ex-dividend date Aug 14, 2026 ($0.02/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 2 open-market buys, 2 sales; latest: Juliana Papa Drinane sold 14,761 shares on Aug 5, 2026.
- Latest filings: 8-K Jul 31, 2026; 10-Q Jul 31, 2026; 8-K Jul 23, 2026.
- Share count: 262.61M shares outstanding (Jul 24, 2026), +1.0% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
OGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 13.75 | 13.77 | 13.75 | 13.76 | 1.98M |
| Oct 14, 2026 | 13.77 | 13.77 | 13.74 | 13.74 | 1.81M |
| Oct 13, 2026 | 13.77 | 13.79 | 13.76 | 13.77 | 2.89M |
| Oct 12, 2026 | 13.80 | 13.80 | 13.76 | 13.77 | 932.30K |
| Oct 9, 2026 | 13.76 | 13.83 | 13.75 | 13.81 | 3.26M |
| Oct 8, 2026 | 13.78 | 13.80 | 13.75 | 13.75 | 2.09M |
| Oct 7, 2026 | 13.72 | 13.79 | 13.72 | 13.79 | 2.21M |
| Oct 6, 2026 | 13.74 | 13.75 | 13.73 | 13.74 | 1.95M |
| Oct 5, 2026 | 13.72 | 13.75 | 13.70 | 13.70 | 2.88M |
| Oct 2, 2026 | 13.71 | 13.75 | 13.71 | 13.72 | 1.92M |
| Oct 1, 2026 | 13.71 | 13.74 | 13.71 | 13.71 | 2.10M |
| Sep 30, 2026 | 13.74 | 13.76 | 13.70 | 13.70 | 2.07M |
| Sep 29, 2026 | 13.73 | 13.75 | 13.72 | 13.74 | 1.63M |
| Sep 28, 2026 | 13.75 | 13.75 | 13.72 | 13.73 | 1.99M |
| Sep 25, 2026 | 13.74 | 13.74 | 13.70 | 13.73 | 1.39M |
| Sep 24, 2026 | 13.72 | 13.74 | 13.72 | 13.72 | 2.22M |
| Sep 23, 2026 | 13.71 | 13.74 | 13.70 | 13.73 | 983.30K |
| Sep 22, 2026 | 13.70 | 13.72 | 13.68 | 13.70 | 1.37M |
| Sep 21, 2026 | 13.70 | 13.76 | 13.67 | 13.68 | 3.12M |
| Sep 18, 2026 | 13.68 | 13.70 | 13.68 | 13.68 | 4.94M |
About Organon
Organon (OGN) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in JERSEY CITY, NJ. Fiscal year ends December 31. SEC CIK 1821825.
OGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carrie Smith Cox | Executive Chair | Nov 13, 2025 |
| Robert Essner | Director | Jun 15, 2026 |
| Alan Ezekowitz | Director | Jun 15, 2026 |
| Helene D Gayle | Director | Jun 15, 2026 |
| Rochelle B Lazarus | Director | Jun 15, 2026 |
| Deborah R Leone | Director | Jun 15, 2026 |
| Philip Ozuah | Director | Jun 15, 2026 |
| Cynthia M Patton | Director | Jun 15, 2026 |
| Ramona Sequeira | Director | Jun 15, 2026 |
| Shalini Sharp | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ferreira Juan Camilo Arjona | Head of R&D & CMO | Aug 12, 2026 |
| Carrie Smith Cox | Executive Chair | Nov 13, 2025 |
| Juliana Papa Drinane | Head of Mfg & Supply | Aug 5, 2026 |
| Aaron Falcione | Chief Human Resources Officer | Apr 2, 2026 |
| Lynette Holzbaur | SVP and Corporate Controller | May 7, 2026 |
| Daniel Karp | Executive VP, Corp. Dev. | Apr 2, 2026 |
| Joseph T. Jr. Morrissey | Interim CEO | Apr 2, 2026 |
| Vittorio Nisita | Head of Global Business Svcs | Apr 2, 2026 |
| Rachel A Stahler | Chief Information Officer | Apr 2, 2026 |
| Matthew M Walsh | Chief Financial Officer | Apr 2, 2026 |
| Kirke Weaver | Gen. Counsel & Corp. Secy. | Apr 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Juliana Papa Drinane | Sale | 14,761 | $13.57 |
| May 6, 2026 | Lynette Holzbaur | Sale | 26,448 | $13.35 |
| May 6, 2026 | Lynette Holzbaur | Buy | 26,448 | $13.35 |
| Nov 12, 2025 | Carrie Smith Cox | Buy | 65,400 | $7.67 |
OGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $6.22B | $187.00M | 0.72 | $700.00M |
| Dec 31, 2024 | $6.40B | $864.00M | 3.33 | $939.00M |
| Dec 31, 2023 | $6.26B | $1.02B | 3.99 | $799.00M |
| Dec 31, 2022 | $6.17B | $917.00M | 3.59 | $858.00M |
| Dec 31, 2021 | $6.30B | $1.35B | 5.31 | — |
Latest balance sheet: total assets $13.18B, total liabilities $12.17B, cash $1.13B (as of Jun 30, 2026).
OGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Apr 30, 2026 | 8-K Item 2.02 (results) | $13.25 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $7.06 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $7.71 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $8.40 |
| May 1, 2025 | 8-K Item 2.02 (results) | $9.45 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $16.32 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $18.78 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on OGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.